Leo gambles on partner’s skin cancer drug even though option agreement is not yet settled
Although Leo Pharma has not yet made a final decision about whether to purchase its partner, Pellepharm - which is behind the company’s first venture into rare skin diseases – the Danish company has already sent more employees to the US to help with the launch.
.jpg)
BY ELIZABETH MØNSTED JOHANSEN, TRANSLATED BY CATHERINE BRETT
If everything goes well with the development of Pellepharm’s treatment for Gorlin syndrome, patidegib, the company will launch the drug in 2022. With this time frame in mind, the company’s Danish partner, Leo Pharma, has now assembled a team to help the small, San Francisco-based company with its launch plans.
Already a subscriber?Log in here
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
With your free trial you get:
- Access all locked articles
- Receive our daily newsletters
- Access our app
.jpg&w=384&q=75)
